TEL AVIV, Israel - May 13, 2019 - TelAve -- VALFIX Medical Ltd. announces the issuance of US Patent No. 10,278,820 titled "Percutaneous valve repair and replacement" issued May 7, 2017. VALFIX Medical is developing trans-catheter solutions for patients suffering from valvular heart disease and heart failure.

"It is exciting to receive this patent as it confirms our technology patentability; our technology is unique and distinct in the market," stated Eli Bar, CEO and Founder of VALFIX Medical. " This patent granted confirms and protects our core technology and adds significant value to our stakeholders"

VALFIX Medical technology is distinguished in its approach to offer both repair and replacement treatment in one procedure. This unique toolbox approach gives more options for interventional cardiologists to deliver the most effective therapy to this complex condition.

Concurrently with the issuance of this patent, VALFIX Medical continues to develop its patent portfolio with other patents in preparation and pending.

More on TelAve News

• REAL Trends + Tom Ferry Announce 2019 America's Best Real Estate Agents List Seventh Annual Real Estate Ranking
• Doug Baruchin of Island Trauma Services, Inc. Earns Accredited ACAC Certification
• Soreide Law Group files a FINRA Arbitration for Florida Investors in GBP Automotive Portfolio, GPB Waste Management, GPB Holdings II & III
• First New Renality Facility Open in Newnan, GA – "City of Homes"
• Stronghold Cyber Security Publishes White Paper on NIST 800-171B for Defense Contractors

About VALFIX Medical:

VALFIX Medical is developing the first complete trans-catheter solution which, based on its multi-wire technology, combines repair and replacement treatments for the Mitral and the Tricuspid valves; offering a viable alternative to open heart surgery.

To learn more about VALFIX Medical visit our website at www.valfixmed.com or contact us directly at info@valfixmed.com

Recently, VALFIX Medical also announced the completion of its second round of investment and the recipience of a Research & Development grant from the Israeli Innovation Authority (https://www.valfixmed.com/blog).